Mineralocorticoids/NNPS
and/CC
mineralocorticoid/NN
receptors/NNS
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
patients/NNS
with/IN
pregnancy-induced/JJ
hypertension/NN
./.

To/TO
examine/VB
the/DT
role/NN
of/IN
mineralocorticoids/NNS
in/IN
the/DT
pathophysiology/NN
of/IN
pregnancy-induced/JJ
hypertension/NN
(/(
PIH/NN
)/)
,/,
we/PRP
studied/VBD
plasma/NN
aldosterone/NN
and/CC
18-hydroxycorticosterone/NN
levels/NNS
in/IN
25/CD
women/NNS
with/IN
PIH/NN
and/CC
25/CD
normal/JJ
pregnant/JJ
women/NNS
,/,
as/IN
controls/NNS
./.
=====
Furthermore/RB
,/,
we/PRP
evaluated/VBD
the/DT
mineralocorticoid/NN
receptor/NN
(/(
MR/NN
)/)
status/NN
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
the/DT
2/CD
groups/NNS
./.
=====
MR/NN
count/NN
was/VBD
significantly/RB
(/(
P/NN
less/JJR
than/IN
0.0005/CD
)/)
decreased/VBN
in/IN
the/DT
PIH/NN
group/NN
(/(
148/CD
+/-/CC
9/CD
binding/VBG
sites/cell/NNS
)/)
compared/VBN
with/IN
the/DT
control/NN
group/NN
(/(
300/CD
+/-/CC
17/CD
binding/VBG
sites/cell/NNS
;/:
mean/NN
+/-/CC
SEM/NN
)/)
./.
=====
Plasma/NN
aldosterone/NN
in/IN
women/NNS
with/IN
PIH/NN
was/VBD
281/CD
+/-/CC
61/CD
pmol/L/NN
;/:
in/IN
normal/JJ
pregnant/JJ
women/NNS
it/PRP
was/VBD
697/CD
+/-/CC
172/CD
pmol/L/NN
(/(
P/NN
less/JJR
than/IN
0.025/CD
)/)
./.
=====
Plasma/NN
18-hydroxycorticosterone/NN
was/VBD
also/RB
significantly/RB
(/(
P/NN
less/JJR
than/IN
0.025/CD
)/)
lower/JJR
(/(
PIH/NN
,/,
1071/CD
+/-/CC
149/CD
pmol/L/NN
;/:
controls/NNS
,/,
1907/CD
+/-/CC
318/CD
pmol/L/NN
)/)
./.
=====
These/DT
values/NNS
were/VBD
determined/VBN
at/IN
the/DT
onset/NN
of/IN
clinical/JJ
symptoms/NNS
of/IN
PIH/NN
./.
=====
These/DT
results/NNS
can/MD
not/RB
be/VB
explained/VBN
by/IN
receptor/NN
down-regulation/NN
due/JJ
to/TO
higher/JJR
levels/NNS
of/IN
mineralocorticoids/NNS
in/IN
PIH/NN
;/:
a/DT
hitherto/RB
unknown/JJ
mineralocorticoid/NN
may/MD
,/,
thus/RB
,/,
be/VB
responsible/JJ
for/IN
the/DT
hypertension/NN
and/CC
altered/JJ
MR/NN
status/NN
./.